| Page 229 | Kisaco Research

Examine how AI models are being developed, validated, and governed to meet regulatory expectations, with practical insights into documentation, auditability, and lifecycle management to ensure safe, transparent, and compliant deployment in GxP environments.

Author:

Benjamin Stevens

Director, CMC Policy
GSK

Benjamin Stevens

Director, CMC Policy
GSK

Explore h ow AI models predict protein 3D structures from sequences, enabling insights into folding pathways and functional conformations
Examine emerging co-folding models that reveal protein–protein interactions and guide multimeric complex design.

Author:

Miles Congreve

Chief Scientific Officer
Isomorphic Labs

Miles Congreve

Chief Scientific Officer
Isomorphic Labs

Learn how AI-driven approaches integrate multiomics data, including genomics, proteomics, and transcriptomics, to identify potential drug targets and disease biomarkers for complex diseases.
Explore how AI models synthesize cross-omic data and real-time multiomic information to uncover novel biological mechanisms, identify potential biomarkers and enable precision medicine.

Moderator

Author:

Eva Fast

Senior Principal Computational Biologist
Pfizer

Eva Fast

Senior Principal Computational Biologist
Pfizer

Author:

Kiran Nistala

Head, Functional Genomics
Alkermes

Kiran Nistala

Head, Functional Genomics
Alkermes

Author:

Harris Bell-Temin

Director, Proteomics
Johnson & Johnson Innovative Medicine

Harris Bell-Temin

Director, Proteomics
Johnson & Johnson Innovative Medicine
Moderator

Author:

David Champagne

Senior Partner
McKinsey & Company

David Champagne

Senior Partner
McKinsey & Company

Author:

Melissa Landon

Head, Commercial & Business Development, AI & Automation
MilliporeSigma

Melissa Landon

Head, Commercial & Business Development, AI & Automation
MilliporeSigma

Author:

David Hallett

Chief Scientific Officer
Recursion

David Hallett

Chief Scientific Officer
Recursion

Author:

Morten Sogaard

Senior Vice President & Head, Astellas Innovation Lab
Astellas Pharma

Morten Sogaard

Senior Vice President & Head, Astellas Innovation Lab
Astellas Pharma

Author:

Peter Clark

Vice President, Digital Chemistry & Design
Novo Nordisk RDUS

Peter Clark

Vice President, Digital Chemistry & Design
Novo Nordisk RDUS

Demonstrate how AI-driven initiatives - like predictive modelling and automated inspection -translate into measurable outcomes (e.g., defect reduction, shorter batch release cycles) that justify capital investment and cross-functional prioritization.

Learn how predictive simulations, generative AI and differentiating clinical biomarkers are forecasted to cut prototyping timelines by weeks and reduce per‑trial costs.

.

Author:

Gregory Goldmacher

Assistant Vice President, Clinical Research, Head, Imaging
Merck

Gregory Goldmacher

Assistant Vice President, Clinical Research, Head, Imaging
Merck

Author:

Hitesh Seth

Chief Architect, Financial Services and Insurance
Salesforce

At Salesforce, Hitesh is responsible for the end-to-end architecture of platforms delivered to financial services and insurance clients globally. His focus is on working with key strategic customers to align Salesforce implementations with their business goals, particularly around the conjunction of Data+AI and CRM. This involves collaborating with retail and commercial banking, payments, wealth management, investment banking, insurance, and capital markets to influence product roadmaps and shape the future of technology in these industries. A significant part of Hitesh's role includes facilitating discussions with CTOs, CIOs, CDOs, and Chief Architects to: •⁠ ⁠Analyze current architectures and design target states. •⁠ ⁠Optimize Salesforce technologies for customer needs. •⁠ ⁠Integrate and Interoperate with Salesforce platforms within broader ecosystems. Being the executive sponsors for the customers, I play a key role in influencing product development within Salesforce by advocating for customer-driven innovations. 

Hitesh oversees end-to-end platform and solution architecture for global financial services and insurance clients. He specializes in aligning Salesforce solutions with strategic business objectives, particularly at the intersection of Data+AI and CRM. By collaborating with retail and commercial banking, payments, wealth management, investment banking, insurance, and capital markets, Hitesh helps influence product roadmaps and shape the future of technology in these industries.

A key part of his role involves engaging CTOs, CIOs, CDOs, and Chief Architects to analyze current architectures, design target states, and optimize Salesforce within broader ecosystems. As an executive sponsor, Hitesh champions customer-driven innovation, ensuring product development meets evolving industry needs.

 

Hitesh Seth

Chief Architect, Financial Services and Insurance
Salesforce

At Salesforce, Hitesh is responsible for the end-to-end architecture of platforms delivered to financial services and insurance clients globally. His focus is on working with key strategic customers to align Salesforce implementations with their business goals, particularly around the conjunction of Data+AI and CRM. This involves collaborating with retail and commercial banking, payments, wealth management, investment banking, insurance, and capital markets to influence product roadmaps and shape the future of technology in these industries. A significant part of Hitesh's role includes facilitating discussions with CTOs, CIOs, CDOs, and Chief Architects to: •⁠ ⁠Analyze current architectures and design target states. •⁠ ⁠Optimize Salesforce technologies for customer needs. •⁠ ⁠Integrate and Interoperate with Salesforce platforms within broader ecosystems. Being the executive sponsors for the customers, I play a key role in influencing product development within Salesforce by advocating for customer-driven innovations. 

Hitesh oversees end-to-end platform and solution architecture for global financial services and insurance clients. He specializes in aligning Salesforce solutions with strategic business objectives, particularly at the intersection of Data+AI and CRM. By collaborating with retail and commercial banking, payments, wealth management, investment banking, insurance, and capital markets, Hitesh helps influence product roadmaps and shape the future of technology in these industries.

A key part of his role involves engaging CTOs, CIOs, CDOs, and Chief Architects to analyze current architectures, design target states, and optimize Salesforce within broader ecosystems. As an executive sponsor, Hitesh champions customer-driven innovation, ensuring product development meets evolving industry needs.

 

Author:

Sandeep Menon

Chief Development Officer
Alnylam

Sandeep Menon

Chief Development Officer
Alnylam

Learn how  GenAI is transforming early drug discovery by designing novel, drug-like small molecules with improved potency, selectivity, and ADME properties.
Explore how GenAI integrates with synthesis planning and automation tools to prioritize viable candidates and accelerate iterative drug development.

Moderator

Author:

Jason Shields

Associate Principal Scientist
AstraZeneca

Jason Shields

Associate Principal Scientist
AstraZeneca

Author:

Christopher D. Taylor

Director of Applied Sciences
Promethium (QC Ware Corp.)

Christopher D. Taylor is Director of Applied Sciences at Promethium (QC Ware Corp.), bringing over 25 years of expertise in density functional theory (DFT). He works with drug discovery teams to bridge AI and quantum chemistry, guiding the deployment of DFT-based rational drug design and descriptor-driven frameworks for drug discovery. Throughout his career, Christopher has used DFT to solve problems once considered unsolvable, and he now highlights how high-quality quantum mechanical data, when used to train AI models, delivers significant gains in accuracy and insight. By translating complex scientific challenges into scalable workflows, he helps accelerate both small molecule and macromolecule design with quantum-level precision.

Christopher D. Taylor

Director of Applied Sciences
Promethium (QC Ware Corp.)

Christopher D. Taylor is Director of Applied Sciences at Promethium (QC Ware Corp.), bringing over 25 years of expertise in density functional theory (DFT). He works with drug discovery teams to bridge AI and quantum chemistry, guiding the deployment of DFT-based rational drug design and descriptor-driven frameworks for drug discovery. Throughout his career, Christopher has used DFT to solve problems once considered unsolvable, and he now highlights how high-quality quantum mechanical data, when used to train AI models, delivers significant gains in accuracy and insight. By translating complex scientific challenges into scalable workflows, he helps accelerate both small molecule and macromolecule design with quantum-level precision.

Author:

Philip Tagari

Chief Scientific Officer
Insitro

Philip Tagari

Chief Scientific Officer
Insitro

Author:

Yue-Wang Webster

Vice President, Model Driven Drug Discovery Platforms
Eli Lilly

Yue-Wang Webster

Vice President, Model Driven Drug Discovery Platforms
Eli Lilly